Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Anti-interleukin-6 therapy in rheumatoid arthritis Woodrick R; Ruderman EMBull NYU Hosp Jt Dis 2010[]; 68 (3): 211-7Recent advances in research have led to significant progress in unraveling the pathophysiology of rheumatoid arthritis (RA), including the cytokine-mediated signaling process. While therapies targeting one particular cytokine, tumor necrosis factor-alpha (TNF-alpha), have revolutionized the treatment of RA, other cytokines, including interleukin 6 (IL-6,) have been implicated in the disease process. In this review, we describe the research that ultimately led to large, randomized, controlled trials demonstrating the effectiveness of tocilizumab, a monoclonal antibody directed against the IL-6 receptor, as a potent new therapeutic agent in RA treatment. These data have shown this agent to be effective both in patients failing non-biologic DMARDs and those failing anti-TNF therapy, although the drug is currently approved for use only in the latter situation. Adverse events seen with tocilizumab therapy are also reviewed.|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/adverse effects/*therapeutic use[MESH]|Antirheumatic Agents/adverse effects/*therapeutic use[MESH]|Arthritis, Rheumatoid/*drug therapy/immunology[MESH]|Evidence-Based Medicine[MESH]|Humans[MESH]|Interleukin-6/*antagonists & inhibitors[MESH]|Randomized Controlled Trials as Topic[MESH]|Treatment Outcome[MESH] |
